SomaLogic

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company was founded by Larry Gold in 2000 and is headquartered in Boulder, CO.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOULDER, Colo., May 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming Jefferies Healthcare Conference.

SomaLogic to Participate in the Jefferies Healthcare Conference

SomaLogic, Inc. (NASDAQ:SLGC ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Adam Taich - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Dan Arias - Stifel Financial Corp. Kyle Mikson - Canaccord Genuity Group Inc. Brandon Couillard - Jefferies Group LLC Operator Good afternoon, and welcome to SomaLogic's First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Q1 2023 Earnings Call Transcript

SomaLogic, Inc. (SLGC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.15 per share a year ago.

SomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue Estimates

SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics market SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics market

SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership

Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan ® Platform at Genomax's Singapore lab

SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

SAN DIEGO--(BUSINESS WIRE)---- $SLGC #CorvexManagement--SomaLogic, Inc.

SomaLogic, Inc. (SLGC) Shareholder Investigation: Robbins LLP is Investigating SomaLogic, Inc. on behalf of Shareholders

BOULDER, Colo., April 20, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce First Quarter 2023 Financial Results on May 11, 2023

SomaLogic, Inc. (NASDAQ:SLGC ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Troy Cox - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Adam Taich - EVP, Life Sciences Business Unit Conference Call Participants Dan Brennan - Cowen Kyle Mikson - Canaccord Genuity Operator Welcome to SomaLogic's Fourth Quarter and Full Year 2022 Earnings Call. All participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript

SomaLogic, Inc. (SLGC) delivered earnings and revenue surprises of 0% and 21.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SomaLogic, Inc. (SLGC) Reports Q4 Loss, Tops Revenue Estimates

BOULDER, Colo., March 28, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter and year ended December 31, 2022 and announced a management transition, as well as the appointment of four new members to the Board of Directors.

SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world's largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. This work builds on a successful history of SomaScan® Platform utilization in some of the world's largest population proteomics biobank projects, including the EPIC, MESA, Fenland, Whitehall II, HUNT3, CRIC, COPD Gene, Spiromics, deCODE and ARIC datasets.

Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples

BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results

BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company. SomaLogic will become the sole provider of high-plex proteomics technology to G42. This initiative spans the United Arab Emirates (UAE) and Kingdom of Saudi Arabia (KSA). As part of the agreement between the two entities G42 will be the first certified site in the Middle East.

SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare

Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific Time Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific Time

SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates

BOULDER, Colo., Dec. 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference

TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan. The new site will offer the 7,000-plex SomaScan® Assay in their labs and provide SomaScan data to their customers. By becoming a SomaLogic Certified Site, FonesLife can now run assays on SomaLogic's SomaScan Platform—the largest commercially available proteomic platform—and accelerate their own research and provide additional opportunities to utilize the industry-leading platform in the Asia-Pacific region.

FonesLife offers the 7,000-plex SomaScan® Platform as Japan's first SomaLogic™ Certified Site

BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) --  SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which will allow institutions around the world to run the 7,000-plex SomaScan® Assay in their own labs. By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic's SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as a service provider. SomaLogic Certified Sites receive support services, on-site training and equipment servicing.

Proteomics labs worldwide can now access SomaLogic's industry-leading 7,000-plex SomaScan® Assay with the Certified Site program

SomaLogic, Inc. (NASDAQ:SLGC ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Roy Smythe - Chief Executive Officer Shaun Blakeman - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Evan Stampler - Stifel Dan Brennan - Cowen Operator Good morning, and welcome to SomaLogic's Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SomaLogic, Inc. (SLGC) Q3 2022 Earnings Call Transcript

SomaLogic, Inc. (SLGC) delivered earnings and revenue surprises of 10% and 113.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SomaLogic, Inc. (SLGC) Reports Q3 Loss, Tops Revenue Estimates

BOULDER, Colo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today reported financial results for the quarter ended September 30, 2022.

SomaLogic Reports Third Quarter 2022 Financial Results

Ardagh Metal Packaging SA

Bed Bath & Beyond

GrowGeneration Corp

Kinross Gold

Marinus Pharmaceuticals

Nu Holdings

Olaplex Holdings

Opendoor

Redfin

More penny stocks with unusual options activity right now. The post 10 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

10 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

SomaLogic and prominent research partners will lead five sessions about CVD and other leading causes of death SomaLogic and prominent research partners will lead five sessions about CVD and other leading causes of death

SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease

BOULDER, Colo., Oct. 27, 2022 (GLOBE NEWSWIRE) -- In a recent paper published earlier this month in Nature Scientific Reports, researchers at the National Institutes of Health conducted what may be the largest technical assessment to date of the 7K SomaScan® Platform to measure its performance and to support the platform's growing community of users. The researchers found the platform's extensive proteome coverage, sensitivity and consistently low variability to be particular strengths, and describe these strengths as key advantages over other proteomic approaches.

SomaLogic's 7K SomaScan® Platform receives high marks in independent technical assessment by researchers at the National Institutes of Health

BOULDER, Colo. and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will host a corresponding audio webcast beginning at 8:30 a.m. ET.

SomaLogic to Announce Third Quarter 2022 Financial Results

BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022.

News for SomaLogic Stock (SLGC)